Drug Combinations - Specifically Targeted Antiviral Therapy For HCV (STAT-C)
 8 Projects
 COMPANY DRUG Research Preclin Phase 1 Phase 2 Phase 3 NDA
Vertex
trial status
Telaprevir (VX-950) Protease Inhibitor plus VX-222 Non-nucleoside Polymerase inhibitor w&wo Ribavirin and peginterferon
Phase 2
Bristol-Myers Squibb
trial status - more
BMS-790052 NS5A Inhibitor plus BMS-650032 Protease Inhibitor w&wo Ribavirin and peginterferon
Phase 2
Gilead
trial status
GS 9190 NN Polymerase Inhibitor plus GS 9256 Protease Inhibitor w&wo Ribavirin and peginterferon
Phase 2
Bristol-Myers Squibb / Pharmasset
BMS-790052 NS5A inhibitor plus PSI-7792 Nucleotide Polymerase inhib. w&wo Ribavirin Phase 2
Boehringer Ingelheim
trial status
BI 201335 Protease Inhibitor plus BI 207127 Polymerase inhib. w&wo Ribavirin
Phase 1
Idenix
trial status
IDX184 Nucleoside Polymerase Inhibitor plus IDX320 Protease Inhibitor
Phase 1 Complete
Hoffmann-La Roche
trial status
R7128 (RO5024048) Nucleoside Polymerase Inhibitor plus ITMN-191 R7227 (RO5190591) Protease inhibitor
Phase 1
Pharmasset

PSI-7977 a pyrimidine and PSI-938 a purine nucleotide analog polymerase inhibitors Phase 1
 Specifically Targeted Antiviral Therapy For HCV (STAT-C)
 Drugs That Directly Target The Hepatitis C Virus - 96 Projects
 COMPANY DRUG Research Preclin Phase 1 Phase 2 Phase 3 NDA
Vertex
Incivek (Telaprevir VX-950) Protease Inhibitor
Approved
Vertex
VX-222 Non-nucleoside Polymerase inhibitor (from ViroChem Pharma)
Phase 2
Vertex
VX-985 Protease Inhibitor
Phase 1 Complete
Vertex / Alios
ALS-2200 HCV NS5B polymerase inhib.
Pre Clinical
Vertex / Alios
ALS-2158 HCV NS5B polymerase inhib.
Pre Clinical
Merck

Victrelis (Boceprevir SCH503034) Protease inhibitor
Approved
Merck

Vaniprevir MK-7009 protease inhibitor Phase 2
Sirna Therapeutics (aquired by Merck)
SIRNA-034 RNAi RNA interference
Pre Clinical
Isis / Merck

MK-0608 nucleoside polymerase inhib.
Phase 1
Intermune / Roche

Protease inhibitor ITMN-191 R7227 (RO5190591)
Phase 2
Intermune
2nd Gen. Protease inhibitor Pre Clinical
Roche / Pharmasset

R7128 (RO5024048) nucleoside polymerase inhibitor
Phase 2
Roche / Ligand (Metabasis)
RG7348 nucleoside Phase 1
Roche / Medivir
HCV polymerase inhibitor
R & D
Medivir / Tibotec
/ JnJ
TMC435 Protease inhibitor Phase 3
Medivir / Tibotec
TMC649128 Nucleoside NS5B polymerase inhibitor
Phase 1
Pfizer

PF-868554 Non-Nuc Polymerase inhibitor
Phase 2
Pfizer

PF-4878691
Phase 1
Tacere Bio / Benitec / Pfizer
RNA interference TT033
Pre Clinical
Boehringer Ingelheim
BI 201335 protease inhibitor
Phase 3
Boehringer Ingelheim

BI 207127 Polymerase inhib.
Phase 1
Intercell / Novartis

IC41 Therapeutic Vacccine Phase 2
Bristol-Myers Squibb
BMS-790052 NS5A Inhibitor
Phase 2
Bristol-Myers Squibb

BMS-791325 Protease inhibitor
Phase 1
Bristol-Myers Squibb

BMS-650032 NS3 Inhibitor
Phase 2
Bristol-Myers Squibb

BMS-824393
Phase 2
Anadys

ANA598 Polymerase inhib
Phase 2
ViroChem Pharma
(acquired by Vertex)
VCH-759 Non nuc Polymerase inhib
Phase 1 backup for VX-222
Globeimmune

GI 5005 Therapeutic Vaccine
Phase 2
iTherX
(formerly Immusol)
ITX5061 Entry Inhibitor Phase 2
iTherX
ITX4520 Entry Inhibitor
Pre Clinical
iTherX
Viral Envelop & Host Cell Receptor Entry Inhibitors
R & D
Idenix

IDX184 Nucleoside Polymerase Inhibitor
Phase 2
Idenix

Protease Inhibitor
IDX320
Phase 1 Halted
Idenix

Non-Nuc Polymerase Inhibitor
IDX375
Phase 1
Idenix

NS5A Inhibitors

Pre Clinical
Abbott

A-837093 Non-nuc polymerase inhib
Phase 1
Gilead

GS 9190 non-nuc polymerase inhibitor
Phase 2
Gilead
GS 9256 Protease Inhibitor
Phase 2
Gilead
Protease
polymerase inhib
R & D
Achillion Gilead
ACH-1095 NS4A Antagonist Pre Clinical
Achillion

ACH-1625 Protease inhibitor
Phase 2
Achillion

ACH-2684 Protease inhibitor
Pre Clinical
Achillion

ACH-2928 NS5A inhibitor
Pre Clinical
Presidio

PPI-461
NS5A inhibitor
Phase 1
Presidio
PPI-1301 NS5A inhibitor
Pre Clinical
Aethlon Medical

Hemopurifier
Phase 1
Transgene

TG4040 (MVA-HCV) Therapeutic Vaccine
Phase 2
ChronTech Pharma (Tripep) / Inovio

Therapeutic Vaccine Chronvac-C
Phase 2
Arrow Therapeutics (aquired by AstraZeneca)
AZD7295 NS5A inhibitor Phase 2
Arrow Therapeutics

Polymerase Inhibitor
Pre Clinical
Arrow Therapeutics

Protease Inhibitor
R & D
U of Mass. Med School

MBL-HCV1
human monoclonal antibody
Phase 2
Eiger BioPharmaceuticals
Clemizole NS4B-RNA Binding Inhibitor
Phase 1
Eiger BioPharmaceuticals
Amphipathic Helix Inhibitors
Pre Clinical
Santaris Pharma
SPC3649 Locked Nucleic Acid mRNA122 inhibitor
Phase 1
GENimmune (subsidiary of Innogenetics)
GNI-103 Therapeutic vaccine
Pre Clinical
GENimmune

GNI-104 - monoclonal antibodie E1 protein
R & D
ChemDiv / IDialog
ID-12 small molecule Pre Clinical
GlaxoSmithKline (Genelabs)
GSK625433 Polymerase Inhibitor
Phase 1
GlaxoSmithKline
Non-nucleoside & nucleoside polymerase inhib.
Pre Clinical
GenPhar

Vaccine Pre Clinical
Abbott / Enanta

ABT-450 Protease inhib Phase 2
Abbott
ABT-072 Non-Nucleoside Polymerase Inhibitor
Phase 2
Abbott
ABT-333 Non-Nucleoside Polymerase Inhibitor
Phase 2
Pharmasset

PSI-7977 nucleoside polymerase inhib.
Phase 2
Inhibitex

INX-189 Polymerase inhibitor
Phase 1 Complete
Pharmasset

PSI-938 nucleoside polymerase inhib.
Phase 1
Enanta

EDP-239 NS5A Polymerase Inhibitor
Pre Clinical
Enanta

Cyclophilin binder
R & D
Dynavax

Immunostimulatory sequences
SD-101 Type C TLR9 agonist
Phase 1
Compass Biotechnologies (Cyplasin / C-Pharma)
VLP vaccine Phase 1
Phenomix

protease inhibitor
Pre Clinical
Samaritan Pharmaceuticals

SP-30 entry inhibitor
Pre Clinical
Avila Therapeutics
AVL-181
protease inhibitor
Pre Clinical
Avila Therapeutics
AVL-192 protease inhibitor
Pre Clinical
Altor BioScience

Soluble T-cell Antigen Receptor
Pre Clinical
Arisyn Therapeutics

ATI-0810 (Formerly PG301029)
RNA and protein production inhibitor
Pre Clinical
Progenics

PRO 206
entry inhibitor
Pre Clinical
BioWest (Migenix)

N-nucleoside Poly inhib
Pre Clinical inactive
PTC / Merck (Schering)

IRES inhib
Pre Clinical
Vertex

Helicase inhibitor
R & D
Cetek

small molecule
R & D
Itherx (Immusol)/ Novartis

ITX2155 l
R & D
Argos Therapeutics

Therapeutic Vaccine R & D
Tibotec

Polymerase inhib. R & D
Regulus Therapeutics
(Alnylam
/ Isis)GlaxoSmithKline
microRNA antagonism of
miR-122
R & D
CombiMatrix

RNAi R & D
Boehringer Ingelheim / Biota
Nucleoside analogues
R & D
BioLeap

????
R & D
Biotron

targeting HCV-p7
R & D
NanoViricides

HepaCide-I
R & D
Hanall

Antihepatitis agents
R & D
Astex Therapeutics

Enzyme Inhibitor R & D
Avexa / TargetDrug

replication inhib.
R & D
StemCells Inc

HCV resistant
Human liver engrafting cells
R & D
Vertex
VX-500 protease inhibitor
Phase 1
Vertex

VX-813 2nd gen protease inhibitor
Pre Clinical
Chiron / CSL

Therapeutic Vaccine CSL123
Phase 2
Biocryst

Polymerase inhibitor
Pre Clinical
ViRex Medical

Hepavaxx C Therapeutic Vaccine
Pre Clinical
Genmab

HuMax-HepC antibody
Pre Clinical
Protiva Biotherapeutics
siRNA
Pre Clinical
Phenomix

PHX1766 protease inhibitor Phase 1
 Immune Modifiers and Other Non-specific Drugs - 37 Projects
 COMPANY DRUG Research Preclin Phase 1 Phase 2 Phase 3 NDA
Human Genome Sciences
ZALBIN (Albuferon albinterferon alfa-2b) (interferon / albuminfusion)
Phase 3
SciClone Pharma

SCV-07
immunomodulator - STAT3 signaling inhibitor
Phase 2
Migenix

MX3235 Celgosivir alpha-glucosidase I inhibitor
Phase 2 inactive
Intarcia

Omega Interferon Phase 2
NABI

Polyclonal antibody
Civacir
Phase 2
Romark Laboratories

Alinia (Nitazoxanide)
Phase 3
Biolex / OctoPlus
Locteron controlled release interferon
Phase 2
Kemin Pharma

KPE02001003 Phase 2
Kemin Pharma

KPE00001113
R & D
VioQuest Pharmaceuticals

Lenocta (sodium stibogluconate
SSG)
Phase 2
Conatus

CTS-1027 MMP inhibitor
Phase 2
Jenkin

JKB-122 antiinflammatory
Phase 2
Oklahoma University
Health Sciences Center
Fluvastatin
Phase 2
Antipodean

Mito-Q antiinflammatory
Phase 2 Complete
Phynova

PYN17 antiviral anti-inflammatory anti-fibrotic
Phase 2
Canopus

CB5300 antiviral
Phase 2
Medtronic

continuous subcutaneous interferon
external pump infusion system
Phase 2
Flamel Technologies
Medusa polymer controled release Interferon alpha-2b XL
Phase 2
Phynova

PYN18 anti viral plant extract
Pre Clinical
Can-Fite
CF102 antiinflammatory
Phase 2
Biotron

BIT225 Phase 1
Peregrine Pharm

Bavituximab Phase 2
Amarillo Bioscience / CytoPharm
Low Dose Oral Interferon Phase 2
Bristol-Myers Squibb
(was owned by ZymoGenetics)
PEG-Interferon lambda Phase 2
Novelos

NOV-205 immunomodulating and antiinflammatory
Phase 2
Scynexis

SCY-635 cyclophilin inhibitor
Phase 1
Idera

IMO-2125 TLR9 Agonist
Phase 1
Anadys

ANA773 TLR7 agonist
Phase 1
Novartis / Debiopharm

Debio 025 Cyclophilin Inhibitor
Phase 3
Bristol-Myers Squibb / Ono
MDX-1106 (ONO-4538) anti-PD1
Phase 1
Cytheris

CYT107
Interleukin-7
Phase 2
Cubist

CB-183872 Protein therapeutic - Formerly IB657 (Illumigen Biosciences)
Pre Clinical
REPLICor
REP 9C broad-spectrum entry inhibitor
Phase 1
Nautilus

Oral Belerofon
R & D
Anadys

AN 025-1
R & D
Genodyssee

GEA007.1 IFN alpha variant
Pre Clinical
Alios BioPharma

Glycoferon
Pre Clinical
SciClone Pharma / Sigmatau
Zadaxin - thymalfasin
Phase 3
Bioenvision

Suvus Phase 2
Enzo Biochem

Immune Regulator ECH18
Phase 1
Immunomedics

IMMU 105 Phase 1
Transition Therapeutics
IET Interferon Enhancing Therapy
Phase 2